
    
      Study design: prospective, randomized, single-blind, placebo-controlled trial

      Inclusion criteria:

      Men and women (older than 18 years old) with type 2 diabetes and inadequate glycemic control,
      defined by HbA1C 8% ³ £10%.

      Previous medications include any oral hypoglycemic agents, as monotherapy or in combination.

      Concurrent lipid-lowering, anti-hypertensive and other medications are allowed

      Exclusion criteria (before the study):

      Type 1 diabetes mellitus Pregnant or lactating women Insulin treatment 3 months prior to
      study entry Creatinine >2 mg/dL Abnormal liver function tests GOT>X2 or GPT>X2 the upper
      normal limit Unstable anginal syndrome Congestive heart failure (NYHA class I-IV) Inability
      to follow study instructions including low compliance

      Exclusion criteria (during the study):

      Severe hypoglycemia (less than 50 mg%) or any hypoglycemic event requiring intravenous
      glucose infusion

      Number of patients: 30 patients (drug) 30 patients (placebo)

      Design:

      Four out-patient visits, at enrollment and every month thereafter At enrollment (visit 1)
      physical examination will be performed and a full set of blood tests will be withdrawn At 1
      week (visit 2) adjustment of hypoglycemic medications will be done and full chemistry and
      blood count will be taken At 6 weeks (visit 3) adjustment of hypoglycemic medications will be
      done and full chemistry and blood count will be taken At 12 weeks (visit 4), the end of the
      study, physical examination will be performed and a full set of blood tests will be withdrawn
      On the 2nd 3rd and 4th visits pill-count will be performed Glucose monitoring: patients will
      be asked to monitor fasting glucose levels at home, in the morning, on a daily basis

      Drugs: identical drug containing/ placebo capsules Drugs for a month will be given in each
      monthly visit

      Dose: 2 tablets three times daily
    
  